Synthesis, anticonvulsant properties and 5-HT1A/5-HT2A receptor affinity of new N-[(4-arylpiperazin-1-yl)-propyl]-2-aza-spiro[4.4] nonane and [4.5]decane-1,3-dione derivatives

Pharmacological Reports

Volumn 57, Issue 3, 2005, Pages 336-344

  Obniska, Jolanta ^a   Kołaczkowski, Marcin ^a   Charakchieva Minol, Sijka ^b   Nedza, Krystyna ^b   Dybała, Małgorzata ^a   Bojarski, Andrzej J ^b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

5 HT1A 5 HT2A receptor ligands; Anticonvulsant activity; Arylpiperazine; Spirosuccinimide

Indexed keywords

2 [3 [4 (2 FLUOROPHENYL)PIPERAZIN 1 YL]PROPYL] 2 AZASPIRO[4.4]NONANE 1,3 DIONE DERIVATIVE; 2 [3 [4 (2 FLUOROPHENYL)PIPERAZIN 1 YL]PROPYL] 7 METHYL 2 AZASPIRON[4.5]DECANE 1,3 DIONE DERIVATIVE; 2 [3 [4 (3 CHLOROPHENYL)PIPERAZIN 1 YL]PROPYL] 7 METHYL 2 AZASPIRO[4.5]DECANE 1,3 DIONE DERIVATIVE; 4 AMINOBUTYRIC ACID A RECEPTOR; ANTICONVULSIVE AGENT; CENTRAL DEPRESSANT AGENT; N [(4 ARYLPIPERAZIN 1 YL)PROPYL] 2 AZASPIRO[4.4]NONANE 1,3 DIONE DERIVATIVE; N [(4 ARYLPIPERAZIN 1 YL)PROPYL] 2 AZASPIRO[4.5]DECANE 1,3 DIONE DERIVATIVE; PIPERAZINE DERIVATIVE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTICONVULSANT ACTIVITY; ARTICLE; BINDING ASSAY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ELECTRIC SHOCK; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROTOXICITY; NONHUMAN; SEIZURE; SEROTONINERGIC SYSTEM;

EID: 22744444797     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Alexander MS, Stables JP, Ciechanowicz-Rutkowska M, Hursthouse MB, Hibbs DE, Edafiogho IO, Moore VA et al: Spiranes 6. Ring A homologues of N-benzyloxy-2-azaspiro[4,4]nonane-1,3-dione. Synthesis, X-ray analysis and anticonvulsant evaluation. Eur J Med Chem, 1996, 31, 787-795.
2. Bagdy E, Kiraly I, Harsing LG: Reciprocal innervation between serotonergic and GABAergic neurons in raphe nuclei of the rat. Neurochem Res, 2000, 25, 1465-1473.
3. Barnes NM, Sharp T: A review of central 5-HT receptors and their function. Neuropharmacology, 1999, 38, 1083-1152.
4. Beck SG, Choi KC: 5-Hydroxytryptamine hyperpolarizes CA3 hippocampal pyramidal cells through an increase in potassium conductance. Neurosci Lett, 1991, 133, 93-96.
5. Bobula B, Zahorodna A, Bijak M: Different receptor subtypes are involved in the serotonin-induced modulation of epileptiform activity in rat frontal cortex in vitro. J Physiol Pharmacol, 2001, 52, 265-274.
6. 2 receptor affinity of some 2- and 3-substituted 1,2,3,4-tetrahydro-β-carbolines. Pharmazie, 1993, 48, 289-294.
7. Cheng Y, Prusoff WH: Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol, 1973, 22, 3099-3108.
8. Edafiogho IO, Scott KR, Moore JA, Farrar VA, Nicholson JM: Synthesis and anticonvulsant activity of imidooxy derivatives. J Med Chem, 1991, 34, 387-392.
9. Estrada E, Pena A: In silico studies for the rational discovery of anticonvulsant compounds. Bioorg Med Chem, 2000, 8, 2755-2770.
10. Filakovszky J, Gerber K, Bagdy G: A serotonin-1A receptor agonist and an N-methyl-D-aspartate receptor antagonist oppose each others effects in a genetic rat epilepsy model. Neurosci Lett, 1999, 261, 89-92.
11. Gariboldi M, Tutka P, Samanin R, Vezzani A: Stimulation of 5-HT1A receptors in the dorsal hippocampus and inhibition of limbic seizures induced by kainic acid in rats. Br J Pharmacol, 1996, 119, 813-818.
12. Glennon RA, Naiman NA, Lyon RA, Titeler M: Aryl-piperazine derivatives as high-affinity 5-HT1A serotonin ligands. J Med Chem, 1988, 31, 1968-1971.
13. Graf M, Jakus R, Kantor S, Levay G, Bagdy G: Selective 5-HT1A and 5-HT7 antagonists decrease epileptic activity in the WAG/Rij rat model of absence epilepsy. Neurosci Lett, 2004, 359, 45-48.
14. Green AR, Misra A, Murray TK, Snape MF, Cross AJ: A behavioral and neurochemical study in rats of the pharmacology of loreclezole, a novel allosteric modulator of the GABAA receptor. Neuropharmacology, 1996, 35, 1243-1250.
15. Kupferberg HJ: Antiepileptic drug development program: a cooperative effort of government and industry. Epilepsia, 1989, 30, Suppl 1, S51-S56.
16. Leppik IE: Antiepileptic drugs in development: prospects for the near future. Epilepsia, 1994, 35, Suppl 4, S29-S40.
17. Lu KT, Gean PW: Endogenous serotonin inhibits epileptiform activity in rat hippocampal CA1 neurons via 5-hydroxytryptamine1A receptor activation. Neuroscience, 1998, 86, 729-737.
18. Obniska J, Kulig K, Zejc A: Synthesis and anticonvulsant properties of new N-piperazinylalkyl imides of succinic acid. Acta Pol Pharm, 1998, 55, 223-231.
19. Obniska J, Pawłowski M, Kołaczkowski M, Czopek A, Duszyńska B, Kłodzińska A, Tatarczyńska E et al.: Synthesis and 5-HT1A/5-HT2A receptor activity of new N-[3-(4-phenylpiperazin-1-yl)-propyl] derivatives of 3-spiro-cyclohexanepyrrolidine-2,5-dione and 3-spiro-beta-tetralonepyrrolidine-2,5-dione. Pol J Pharmacol, 2003, 55, 553-557.
20. Obniska J, Zagórska A: Synthesis and anticonvulsant properties of new N-[(4-arylpiperazin-1-yl)-methyl] derivatives of 3-aryl pyrrolidine-2,5-dione and 2-aza-spiro[4.4]-nonane-1,3-dione. Farmaco, 2003, 58, 1227-1234.
21. Obniska J, Zejc A: Synthesis, physicochemical and anti-convulsant properties of some N-substituted amides of 3-spirocycloalkylpyrrolidine-2,5-dione. Acta Pol Pharm, 2002, 60, 383-390.
22. Obniska J, Zejc A, Karolak-Wojciechowska J: Synthesis, physicochemical and anticonvulsant properties of new N-pyridyl derivatives of 3-phenyl- and 3,3-diphenyl-succinimides. Farmaco, 1999, 54, 423-429.
23. Obniska J, Zeic A, Zagórska A: Synthesis and anticonvulsant properties of new 1-phenyl and 1-phenylamino-3-phenylpyrrolidine-2,5-dione derivatives. Acta Pol Pharm, 2002, 59, 209-213.
24. Okuhara DY, Beck SG: 5-HT1A receptor linked to inward-rectifying potassium current in hippocampal CA3 pyramidal cells. J Neurophysiol, 1994, 71, 2161-2167.
25. Perucca E: The new generation of antiepileptic drugs: advantages and disadvantages. Br J Clin Pharmacol, 1996, 42, 531-543.
26. Rogawski MA: Principles of antiepileptic drug action. In: Antiepileptic Drugs, 5th edn. Ed. Levy RH, Mattson RH, Meldrum BS, Perucca E, Lippincott Williams & Wilkins, Philadelphia, Baltimore, New York, 2002, 4-17.
27. Scott KR, Edafiogho IO, Moore JA, Moore VA, Nicholson JM: Synthesis and anticonvulsant activity of a spiro-succinimide. Pharm World J, 1991, 8, 44-50.
28. Soderpalm B, Andersson G, Enerback C, Engel JA: In vivo administration of the 5-HT1A receptor agonist 8-OH-DPAT interferes with brain GABA(A)/benzodiazepine receptor complexes. Neuropharmacology, 1997, 36, 1071-1077.
29. Stables JP, Kupferberg HJ: The NIH Anticonvulsant Drug Development (ADD) Program: Preclinical Anticonvulsant Screening project. In: Antiepileptic Drugs, 4th edn. Ed. Levy RH, Mattson RH, Meldrum. BS, Raven Press, New York, 1995, 4-17.
30. Theodore WH: Does serotonin play a role in epilepsy? Epilepsy Curr, 2003, 3, 173-177.
31. Tokarski K, Zahorodna A, Bobula B, Hess G: Comparison of the effects of 5-HT1A and 5-HT4 receptor activation on field potentials and epileptiform activity in rat hippocampus. Exp Brain Res, 2002, 147, 505-510.
32. Wada Y, Nakamura M, Hasegawa H, Yamaguchi N: Intra-hippocampal injection of 8-hydroxy-2-(di-n-propyloamino)-tetralin (8-OH-DPAT) inhibits partial and generalized seizures induced by kindling stimulation in cats. Neurosci Lett, 1993, 159, 179-182.
33. Yan QS, Yan SE: Serotonin-1B receptor-mediated inhibition of [(3)H]GABA release from rat ventral tegmental area slices. J Neurochem, 2001, 79, 914-922.